Compared to traditional chemotherapy, inhibitors targeting the USP5/YBX3 interaction or the lysosomal pathway may reduce systemic toxicity, providing a new approach for the precision treatment of CRC. The gene discussed is USP5; the disease is colorectal carcinoma.